IRIS
TOGNOLINI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.485
AS - Asia 6.522
EU - Europa 6.386
SA - Sud America 916
AF - Africa 394
Continente sconosciuto - Info sul continente non disponibili 243
OC - Oceania 2
Totale 24.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.233
SG - Singapore 2.158
IT - Italia 1.932
CN - Cina 1.857
VN - Vietnam 1.094
FI - Finlandia 840
SE - Svezia 766
IE - Irlanda 753
BR - Brasile 723
DE - Germania 662
HK - Hong Kong 444
UA - Ucraina 329
FR - Francia 253
ZA - Sudafrica 250
BD - Bangladesh 226
GB - Regno Unito 200
NL - Olanda 188
TR - Turchia 184
IN - India 168
CA - Canada 137
RU - Federazione Russa 115
AR - Argentina 80
BE - Belgio 65
AT - Austria 64
CI - Costa d'Avorio 56
MX - Messico 56
JP - Giappone 49
ID - Indonesia 46
IQ - Iraq 45
KR - Corea 37
RO - Romania 36
CZ - Repubblica Ceca 35
EC - Ecuador 35
PH - Filippine 34
ES - Italia 32
TH - Thailandia 29
PK - Pakistan 27
PL - Polonia 25
VE - Venezuela 20
JO - Giordania 19
LT - Lituania 18
CM - Camerun 17
CO - Colombia 17
MA - Marocco 15
SA - Arabia Saudita 14
CL - Cile 13
TN - Tunisia 13
EG - Egitto 12
JM - Giamaica 12
CH - Svizzera 11
UZ - Uzbekistan 11
CR - Costa Rica 10
MY - Malesia 10
EU - Europa 9
HN - Honduras 9
PA - Panama 9
AL - Albania 8
BO - Bolivia 8
KE - Kenya 8
NP - Nepal 8
PY - Paraguay 8
AZ - Azerbaigian 7
HU - Ungheria 7
KG - Kirghizistan 7
PE - Perù 7
TW - Taiwan 7
BG - Bulgaria 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
KZ - Kazakistan 5
LB - Libano 5
PT - Portogallo 5
SI - Slovenia 5
SN - Senegal 5
DO - Repubblica Dominicana 4
EE - Estonia 4
GR - Grecia 4
HR - Croazia 4
IR - Iran 4
PS - Palestinian Territory 4
RS - Serbia 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
SV - El Salvador 3
UY - Uruguay 3
AU - Australia 2
BB - Barbados 2
CY - Cipro 2
GA - Gabon 2
KH - Cambogia 2
LV - Lettonia 2
NG - Nigeria 2
QA - Qatar 2
Totale 24.697
Salva come PNG Salva come JPEG
Città #
Dallas 2.975
Singapore 1.141
Ashburn 810
Dublin 745
San Jose 745
Chandler 737
Parma 542
Santa Clara 519
Beijing 435
Ann Arbor 434
Hong Kong 414
Jacksonville 360
Ho Chi Minh City 350
Dearborn 309
Boardman 267
Hanoi 250
Council Bluffs 248
Johannesburg 238
Munich 234
New York 182
Los Angeles 174
Nanjing 156
Shanghai 154
Izmir 151
Milan 148
Helsinki 137
Princeton 130
Hefei 128
Lauterbourg 124
Wilmington 110
Bremen 107
Bologna 103
San Mateo 79
São Paulo 71
Buffalo 68
Toronto 63
Shenyang 59
Brussels 58
Columbus 58
Kunming 57
Moscow 57
Abidjan 56
Rome 53
Vienna 52
Hebei 48
Jinan 48
Nanchang 47
Modena 46
Guangzhou 43
Turku 43
Frankfurt am Main 42
Haiphong 42
Seattle 41
Tokyo 41
Da Nang 40
Chicago 37
London 35
Woodbridge 35
Bengaluru 34
Rio de Janeiro 33
Des Moines 32
Brescia 31
Orem 30
Changsha 29
The Dalles 29
Tianjin 29
Jiaxing 28
Bangalore 27
Seoul 27
Phoenix 26
Brooklyn 25
Hangzhou 24
Jakarta 24
Montreal 24
Nuremberg 24
Fremont 23
Houston 23
Reggio Emilia 23
Lubbock 21
Belo Horizonte 20
Boston 20
Düsseldorf 20
Mexico City 20
Stockholm 20
Turin 20
Florence 19
Ottawa 19
Piacenza 19
Brno 18
Denver 17
Grafing 17
Amman 16
Amsterdam 16
Atlanta 16
Pune 16
Warsaw 16
Biên Hòa 15
Brasília 15
Chennai 15
Hillsboro 15
Totale 15.811
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.720
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.693
Principi di farmacognosia e fitoterapia. Seconda edizione 778
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 302
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 263
Principi di farmacognosia e fitoterapia 263
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 260
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 256
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 255
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 248
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 244
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 228
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 226
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 224
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 221
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 221
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 220
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 215
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 207
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 204
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 203
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 199
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 199
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 198
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 196
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 194
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 191
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 190
A simple GC-MS method for the screening of betulinic, corosolic, maslinic, oleanolic and ursolic acid contents in commercial botanicals used as food supplement ingredients 190
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 189
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 182
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 181
Enhanced photosensitizing properties of protein bound curcumin 181
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 180
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 180
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 178
inibitori eph-ephrin biodisponibili oralmente 177
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 177
A photosensitizing fusion protein with targeting capabilities 177
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 175
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 173
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 170
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 168
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 168
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 165
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 165
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 165
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 163
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 162
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 161
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 160
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 160
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 160
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 159
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 157
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction 157
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 156
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 154
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 153
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 153
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 152
Structure activity relationship of new EphA2 ligands 152
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 152
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 152
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 151
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 151
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 150
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 148
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 148
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 147
Discovery of natural extracts interfering with EphA2-ephrinA1 system 146
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 144
Target-hopping: a useful approach to identify novel Eph receptor antagonists 142
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 142
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 141
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 139
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 138
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 138
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 138
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 137
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 136
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 136
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 133
Pharmacological screening of novel antiplatelet agents with analgesic activity 133
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 133
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 130
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 129
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 129
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 128
Are we using the right pharmacological tools to target EphA4? 128
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 127
5-substituted derivatives of 6-amino-1,3-diphenyl-2-thioxo-2.3-dihydropyrimidin-4(1H9-one as a new class of potent inhibitors of interleukin 8-induced chemotaxis 127
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 126
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 125
PHENYLPROPANOID RICH ESSENTIAL OILS AS POTENTIAL ANTITHROMBOTICS ENDOWED WITH GASTROPROTECTIVE EFFECTS 125
New insights into the pharmacological properties of potent antiplatelet 2-amino-benzo|d|isothiazol-3-one derivatives 125
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 125
6-amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. 124
Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model 123
Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice 123
Totale 20.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.659
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022809 0 31 32 100 41 35 81 87 59 74 57 212
2022/20232.958 330 302 157 237 320 333 64 162 876 43 96 38
2023/20241.195 68 75 32 45 91 229 117 82 60 111 118 167
2024/20254.051 127 197 275 214 398 429 232 242 539 373 360 665
2025/202610.671 730 1.326 2.863 736 1.003 467 869 276 1.107 661 355 278
2026/2027578 285 293 0 0 0 0 0 0 0 0 0 0
Totale 24.948